Prevention strategies and therapeutic options for many viruses are currently inadequate for the successful reduction of disease prevalence, especially in resource-poor settings. VIDD is home to one of the world’s largest vaccine programs that includes vaccine development and clinical trial studies. Several VIDD disciplines, such as virology, epidemiology and statistics, work in concert with the common goal of curbing viral infection.
Select a letter to display a list of Faculty members
Co-infections impact clinical, virological, and immunologic outcomes in HIV. I work on understanding how we can better treat patients to prevent HIV and HIV-associated complications, including focus on HIV persistence and HIV-associated malignancies.
Infections in the immunocompromised host, especially diagnosis, prevention and treatment of CMV, VZV, BK virus, adenovirus, and respiratory virus infections. Research includes understanding the genetic basis of infeciton complications, genome and gene expression studies.
Characterizing T cells induced by candidate vaccines using flow cytometry. Developing new assays to evaluate vaccine efficacy with HIV Vaccine Trials Network. Studies include examining T cell function at the single-cell level using advanced flow cytometric techniques; examples include T cell responses to vaccination and to viral infections such as CMV, EBV, HIV, and hepatitis B.
Statistical and computational methods for bioinformatics applications, statistical modeling for genome sequence analysis and statistical modeling frameworks. The interface between computer science, statistics, and molecular biologyand such as development of new informatics methods in genomics and post-genomics
Current studies include development of methods for T-cell based sieve analysis, quantification of vaccine induced T cell responses, systems biology of influenza and time-dependent correlates analysis of HIV efficacy trial.
Elucidating cellular mechanisms for control of HIV replication, Assessing cellular immune responses in HIV vaccine recipients, Teaching and Mentoring Interests, HIV immunology for experts and the public
Research focus includes vaccine clinical trials, the design and analysis of Phase I/II trials, for evaluating vaccine effects on immune responses; the design and analysis of Phase 2b/III trials, for evaluating vaccine efficacy, immune correlates, sieve analysis, and post-infection vaccine effects; general biostatistical methods research, such as survival analysis, causal inference, and evaluation of surrogate endpoints
Developing methods and tools for high throughput, high dimensional experiments with applications in vaccine research and immunology; flow cytometry, peptide microarrays, next generation sequencing; Bayesian inference and computation and statistical computing
Design, conduct, monitoring, and analysis of multicenter randomized clinical trials and comparative effectiveness studies, measuring and improving the effectiveness of informed consent in clinical research; improving the quality and efficiency of clinical trial data management; clinical research trials for the prevention or treatment of HIV / AIDS and vaccine clinical trials
Clinical and translational investigations relating to infections in immunocompromised hosts, with a focus on disease associations, risk stratification, and diagnostic strategies for viral infections in transplant recipients
Immunologic endpoint determination for experimental vaccines (HIV, pneumococcus, malaria, TB, flu) and
Logistics, operations, quality assurance, and assay validation for immunologic evaluation of vaccines in the clinical trial setting
Research focus includes statistical methods for bioassays (e.g., flow cytometry, sequencing); dynamic modeling of biological systems (e.g., multi-type cell populations, B-cell repertoire); nonparametric methods for supervised and unsupervised learning; stochastic processes (e.g., branching processes); algorithms for scalable data analysis.
Clinically important persistent and latent viral infections; curative therapies for latent viral infections ;diagnosis of disease caused by herpesviruses, enterovirus, JC and BK viruses, parvovirus B19, and hepatitis viruses
Statistical support to clinical research on HSV1 and HSV2 and other herpesvirus infections; Clinical association between herpes and HIV; statistical methods work in areas such as misclassification in time-to-event outcomes, laboratory assay validation, and methods for quantifying and examining risk factors for viral shedding
Natural Killer Cell Receptor Diversity and CMV in Hematopoietic Cell Transplantation; Viral infections after Hematopoietic Stem Cell Transplantation; Epidemiology of invasive Fungal infections in Cord Blood Transplant Recipients and Clinical trials of the prevention of post-transplant infection
Interest in describing the quantitative and dynamical features of human pathogens and immune responses. Most of work to-date is on the pathogenesis of HSV-2 infection but also interested in applying models to optimize viral eradication startegies, and to use models to capture kinetic features of the human microbiome.
Research is focused on the development of a safe and effective vaccine to combat the spread of HIV and to investigate how HIV infection leads to AIDS. Two major areas of research is to better understand how neutralizing antibodies against HIV are developed during natural HIV-infection,and engineer immunogens that will elicit broadly neutralizing antibody responses against HIV.
Epidemiologic studies of infectious disease transmission, vaccine studies and the development of novel statistical methods and designs for studies of infectious disease transmission. Efficacy and effectiveness assessments of control and prevention strategies for infectious diseases of import to global health, including influenza, cholera, dengue, and tuberculosis
Research interests involve mechanisms driving the differentiation of B cells following vaccination and infection, understanding how differences in the pre-immune repertoire influences immunity and vaccine Development
Fred Hutch is proud to be an Equal Opportunity and VEVRAA Employer. We are committed to cultivating a workplace in which diverse perspectives and experiences are welcomed and respected. We do not discriminate on the basis of race, color, religion, creed, ancestry, national origin, sex, age, disability, marital or veteran status, sexual orientation, gender identity, political ideology, or membership in any other legally protected class. We are an Affirmative Action employer. We encourage individuals with diverse backgrounds to apply and desire priority referrals of protected veterans. Read the EEO is the Law poster here.